Piramal Hopes Depth Of Neuraceq Data Will Provide Contrast For Third Alzheimer’s Imaging Agent
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neuraceq will be the third entrant into the beta-amyloid imaging market, a space already limited by concerns about the clinical utility of PET scans in Alzheimer’s disease management.